TABLE 2.
Microbiologic cure at visit 3 and visit 4 (mITT population)
| Visit, clinical response | Result for subjects receiving: |
Rifalazil−azithromycin | |
|---|---|---|---|
| Rifalazil, 25 mg | Azithromycin, 1 g | ||
| Visit 3 | |||
| Total no. of subjects | 33 | 38 | |
| No. (%) cured | 28 (84.8) | 35 (92.1) | (−7.3) |
| No. (%) failed | 5 (15.2) | 3 (7.9) | |
| 95% CI | (72.4; 97.3) | (83.4; 100.0) | (−22.5; 7.9) |
| Visit 4 | |||
| Total no. of subjects | 33 | 38 | |
| No. (%) cured | 26 (78.8) | 31 (81.6) | (−2.8) |
| No. (%) failed | 7 (21.2) | 7 (18.4) | |
| 95% CI | (64.6; 93.0) | (69.0; 94.1) | (−21.7; 16.1) |